Myocarditis in Paediatric Patients: Unveiling the Progression to Dilated Cardiomyopathy and Heart Failure

Inês Teixeira Farinha1, Joana Oliveira Miranda2,3

  • 1Faculty of Medicine of Porto University, Porto 4200-319, Portugal. i.t.farinha@gmail.com.

Insights

Pediatric myocarditis, an inflammation of the heart muscle, can lead to dilated cardiomyopathy. This review explores recent discoveries in pediatric myocarditis, aiding diagnosis and treatment strategies.

Area of Science:

  • Cardiology
  • Pediatric Medicine
  • Pathology

Background:

  • Myocarditis presents a significant health challenge in children, potentially causing severe illness and progressing to dilated cardiomyopathy.
  • Diverse causes exist, with viral infections being most common in developed nations, though bacterial, protozoal infections, and drug hypersensitivity are also implicated.
  • Diagnosing pediatric myocarditis is complex due to a wide range of clinical presentations, from asymptomatic cases to sudden cardiac death.

Purpose of the Study:

  • To review recent advancements in understanding pediatric myocarditis.
  • To explore the disease's progression to dilated cardiomyopathy.
  • To discuss updated diagnostic and therapeutic approaches.

Main Methods:

  • Literature review focusing on recent studies of pediatric myocarditis.
  • Analysis of diagnostic modalities including endomyocardial biopsy and non-invasive tools.
  • Examination of treatment strategies, including the role of intravenous immunoglobulin.

Main Results:

  • Myocarditis pathogenesis exhibits a triphasic nature, influencing management strategies.
  • Endomyocardial biopsy is the definitive diagnostic standard, supported by various non-invasive methods.
  • The efficacy of intravenous immunoglobulin in treating pediatric myocarditis remains under investigation.

Conclusions:

  • Understanding the triphasic nature of myocarditis is crucial for effective patient management.
  • Accurate diagnosis relies on a combination of biopsy and non-invasive techniques.
  • Further research is needed to clarify treatment outcomes, particularly for intravenous immunoglobulin therapy in pediatric cases.

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
591
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
966
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
402
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K